General

• How are PHOs expected to meet requirements from other programmes (such as ordering for chronic care) when the Programme requires totally different results? E.g. requires PHOs to decrease the number of tests. The Programme does expect DHBs to take regional issues into consideration when negotiating the Financial Indicators with the PHOs. However, any expected increases in utilization for pharmaceuticals or laboratory tests should also be reflected in the national forecast. So increases in line with expected national increases would not reflect negatively on PHOs.

• The allocation of funds at a practice level is up to the PHO or DHB? The allocation of funding is at a PHO level however, each PHO needs to have their policy for the use of the performance funding agreed by the DHB in the Performance Plan.

• Is there any differentiation between access and interim PHOs, if not this could be a weakness? The only differentiation is for the benchmark expenditure calculation for the financial indicators.

• What is going to happen with the total amount of funding available for the second phase indicators? When the second phase indicators come out, some of the first indicator set may become information only and then the funding will be reapportioned against the new suite of indicators.
  

Back<<